In addition to suppressing appetite, boosting insulin secretion and slowing stomach emptying, these drugs appear to influence brain pathways involved in food reward and cravings, making them a potential candidate for tackling the loss of control that characterizes binge eating
1 The findings showed: Those not taking GLP-1 medications showed significantly more MS disease progression Higher risk of brainstem dysfunction (4.36% risk difference) Higher risk of cerebellar dysfunction (4.54% risk difference) Higher risk of bowel and bladder dysfunction (4.98% risk difference) As a retrospective analysis, this study has limitations including potential confounding factors, and definitive randomised controlled trials are needed to confirm any disease-modifying effects of GLP-1 medications in MS
This peptide works through mechanisms distinct from VEGF pathway activation
The data from the reporting system often reflect specific patient populations or specific time periods
Some patients report dramatically improved PMS, with reduced bloating, irritability, and breast tenderness